Sales income totaled RON71.5 million, down 25% on the year, and operating expenses stood at RON49.5 million, down 8.4% on the year.
“The result of 2024 is strongly altered by the situation of “one-off” sales of paracetamol-based medicines made in Q1 2023 by Biofarm SA as a result of the shortage of paracetamol-based medicines imported by third parties from external sources”, according to company representatives.
The data comes in the context in which Biofarm’s net profit climbed 8.6% on the year to RON77 million in 2023, and sales income reached RON280.3 million in 2023, up 1.2% on the year.
In April 2024, the ordinary general meeting of Biofarm shareholders approved the distribution of the 2023 net profit and of a gross dividend of RON0.031 per share, which ensures a 3.8% yield, ased on the current share trading price. Overall, the shareholders will receive dividends of RON30.5 million.
Biofarm has a market capitalization of over RON800 million after its shares have lost 1.2% so far in 2024, amid deals worth RON4.4 million, but gained 23% in the last 12 months, amid deals worth RON9 million.
Its shareholders include SIF Muntenia, with an ownership stake of 51.6%, and Lion Capital, with a stake of 36.7%.